Danon disease - A disorder of autophagy as a cause of hypertrophic cardiomyopathy;Danonova nemoc - Porucha autofagie jako přčina hypertrofické kardiomyopatie

Cor et Vasa

Volumn 52, Issue 11-12, 2010, Pages 706-712

  Kubánek, Miloš ^a   Elleder, Milan ^b   Sikora, Jakub ^a,b   Šramko, Marek ^a   Malušková, Jana ^a   Dvořáková, Lenka ^b   Vlášková, Hana ^b   Kotreč, Martin ^a   Vrbská, Jana ^a   Ridzoň, Petr ^c   Šnorek, Michal ^d   Toušek, František ^d   Málek, Ivan ^a   Pirk, Jan ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^d Hospital eské Bud jovice   (Czech Republic)

Author keywords

Danon disease; Hypertrophic cardiomyopathy; LAMP2

Indexed keywords

CREATINE KINASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2;

ADULT; ARTICLE; AUTOPHAGY; CASE REPORT; CZECH REPUBLIC; DANON DISEASE; DISEASE COURSE; ELECTROCARDIOGRAM; FAMILY; GENE MUTATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART PREEXCITATION; HEART TRANSPLANTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE BIOPSY; SKELETAL MUSCLE; SYSTOLIC DYSFUNCTION;

EID: 79952392511     PISSN: 00108650     EISSN: None     Source Type: Journal    
DOI: 10.33678/cor.2010.176     Document Type: Article

References (21)

1. Maron BJ, Seidman JG, Seidman CE. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:21-32.
2. Kettner J. Hypetrofická kardiomyopatie. In: Vojáček J, Kettner J, eds. Klinická kardiologie. Hradec Králové: Nucleus HK, 2009:452-462.
3. Bultas J. Srdce a metabolická onemocnční. In: Vojáček J, Kettner J, eds. Klinická kardiologie. Hradec Králové: Nucleus HK, 2009:856-865.
4. Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 2004;90:842-846. (Pubitemid 39005922)
5. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362-372.
6. Danon MJ, Oh SJ, DiMauro S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981;31:51-57. (Pubitemid 11217453)
7. Nishino I, Fu J, Tamji, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000;406: 906-910. (Pubitemid 30664268)
8. Fanin M, Nascimeni AC, Fulizio L, et al. Generalised lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol 2006;168:1309-1320.
9. Regelsberger G, Höftberger R, Pickl WF, et al. Danon disease: Case report and detection of new mutation. J Inherit Metab Dis 2009 Jul 7. [Epub ahead of print]
10. Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009;301:1253-1259.
11. Toib A, Grange DK, Kozel BA, et al. Distinct clinical and histological presentations of Danon cardiomyopathy in young women. J Am Coll Cardiol 2010;55:408-410.
12. Prall FR, Drack A, Tailor M, et al. Ophthalmic manifestations of Danon disease. Ophthalmology 2006;113:1010-1013. (Pubitemid 43795242)
13. Huynh KK, Eskelinen EL, Scott CC, et al. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J 2007;26:313-324. (Pubitemid 46160933)
14. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy - Heart Failure Society of America Practice Guidelines. J Card Fail 2009;15:83-97.
15. Colombo MG, Botto N, Vittorini S, et al. Clinical utility of genetic testing for inherited hypertrophic and dilated cardiomyopathies. Card Ultrasound 2008;6:62.
16. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:201-211.
17. Čurila K, Pěnička M, Línková H, et al. Molekulární genetika u hypertrofické kardiomyopatie. Cor Vasa 2007;49:138-142.
18. Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006;81:459-467.
19. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008;83;630-638. (Pubitemid 351810562)
20. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010;121:445-456.
21. Judge DP. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA 2009;302:2471-2476.